Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
|Articles|May 1, 2022
A HELPING HAND: Advice on Caring for Someone With Non-Small Cell Lung Cancer From Those Who Do It
Author(s)Sponsored Content
Care partners need help, too! That’s why this informational booklet was created. It’s full of practical advice from people who have been in your shoes, caring for someone with non-small cell lung cancer.
Advertisement
Advertisement
Related to this article
A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.
Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.
AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.
In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.
An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.
Advertisement
Advertisement
Trending on CURE
1
The Growing Role of AI in Cancer Care
2
Finding the Words: How to Talk to Someone With Cancer
3
3 More Lung Cancer Breakthroughs From WCLC 2026
4
Why Some Stage 3 Lung Cancers Don't Respond to Treatment, and What Researchers Are Trying Next
5